Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Jessica DeAngelo"'
Publikováno v:
Annals of Pharmacotherapy. 54:344-350
Background: Limited clinical data exist describing the use of direct-acting oral anticoagulants (DOACs) in patients with body mass index (BMI) >40 kg/m2 or body weight >120 kg. Thus, DOAC therapy in this population remains controversial. Objectives:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7223dd045d672b4657e172bc715443d
https://doi.org/10.1177/1060028019886092
https://doi.org/10.1177/1060028019886092
Autor:
Richard A. Cosgrove, James M. Camamo, Christopher J Edwards, Asad E. Patanwala, Daniel H. Jarrell, Jessica DeAngelo
Publikováno v:
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 75(15)
Purpose Results of a comparison of blood product use and cost outcomes with use of 3-factor versus 4-factor prothrombin complex concentrate (PCC) for indications other than warfarin reversal are presented. Methods Consecutive patients who received 3-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28c2ed6be1ae5924f0d3735e7060d494
https://pubmed.ncbi.nlm.nih.gov/29941507
https://pubmed.ncbi.nlm.nih.gov/29941507
Autor:
Daniel H. Jarrell, Richard A. Cosgrove, Asad E. Patanwala, James M. Camamo, Christopher J Edwards, Jessica DeAngelo
Publikováno v:
American journal of therapeutics. 25(3)
BACKGROUND Prothrombin complex concentrates (PCCs) are drug products containing varying amounts of vitamin K-dependent coagulation factors II, VII, IX, and X. The evidence comparing 3-factor PCC (3-PCC) versus 4-factor PCC (4-PCC) for warfarin revers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40fcc81242fba53662e125d57218ba0b
https://pubmed.ncbi.nlm.nih.gov/28763307
https://pubmed.ncbi.nlm.nih.gov/28763307